A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

Respiratory Medicine

Volumn 104, Issue 1, 2010, Pages 9-21

  Mubarak, Kamal K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Mechanism of action; Pharmacokinetics; Prostacyclin; Pulmonary Arterial Hypertension; Treatment

Indexed keywords

ACT 293987; BERAPROST; BOSENTAN; G PROTEIN COUPLED RECEPTOR; ILOPROST; MRE 269; NS 304; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR; PROSTANOID; PROSTANOID RECEPTOR; SILDENAFIL; THROMBOXANE A2; UNCLASSIFIED DRUG; UNIPROST;

ABDOMINAL PAIN; ANOREXIA; BINDING AFFINITY; BIOEQUIVALENCE; BLEEDING; BUERGER DISEASE; CATHETER INFECTION; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FLUSHING; FOOT PAIN; HEAT; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LUNG; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOGENESIS; PHOTOSENSITIVITY; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RECURRENT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STEADY STATE; TARGET ORGAN; THROMBOSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PROSTAGLANDINS, SYNTHETIC; TREATMENT OUTCOME;

EID: 73749086478     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.015     Document Type: Review

References (98)

1. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
2. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
3. Kleemann E., Schmehl T., Gessler T., Bakowsky U., Kissel T., and Seeger W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm Res 24 (2007) 277-287
4. Kuwano K., Hashino A., Asaki T., Hamamoto T., Yamada T., Okubo K., et al. 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 322 (2007) 1181-1188
5. Badesch D.B., Abman S.H., Ahearn G.S., Barst R.J., McCrory D.C., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 35S-62S
6. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (2009) 1573-1619
7. Denton C.P., Pope J.E., Peter H.H., Gabrielli A., Boonstra A., van den Hoogen F.H., et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007)
8. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
9. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
10. Sitbon O., McLaughlin V.V., Badesch D.B., Barst R.J., Black C., Galie N., et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60 (2005) 1025-1030
11. Thenappan T., Shah S.J., Rich S., and Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30 (2007) 1103-1110
12. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., and Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36 (2004) 1187-1205
13. Schwaner I., Offermanns S., Spicher K., Seifert R., and Schultz G. Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL. Biochim Biophys Acta 1265 (1995) 8-14
14. Mitsui T., Yokoyama S., Shimizu Y., Katsuura M., Akiba K., and Hayasaka K. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation. Thromb Haemost 77 (1997) 991-995
15. Oates J.A., FitzGerald G.A., Branch R.A., Jackson E.K., Knapp H.R., and Roberts II L.J. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 319 (1988) 689-698
16. Castellani S., Paladini B., Paniccia R., Di Serio C., Vallotti B., Ungar A., et al. Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart failure. Am Heart J 133 (1997) 94-100
17. Devillier P., and Bessard G. Thromboxane A2 and related prostaglandins in airways. Fundam Clin Pharmacol 11 (1997) 2-18
18. Moncada S., and Vane J.R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30 (1978) 293-331
19. Fetalvero K.M., Martin K.A., and Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 82 (2007) 109-118
20. Xiao C.Y., Hara A., Yuhki K., Fujino T., Ma H., Okada Y., et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104 (2001) 2210-2215
21. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
22. Doi Y., Minami T., Nishizawa M., Mabuchi T., Mori H., and Ito S. Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. Neuroreport 13 (2002) 93-96
23. Hayes J.S., Lawler O.A., Walsh M.T., and Kinsella B.T. The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J Biol Chem 274 (1999) 23707-23718
24. McLaughlin V.V., Genthner D.E., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
25. Smyth E.M., Austin S.C., Reilly M.P., and FitzGerald G.A. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 275 (2000) 32037-32045
26. Hata A.N., and Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103 (2004) 147-166
27. Walch L., de Montpreville V., Brink C., and Norel X. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol 134 (2001) 1671-1678
28. Davis R.J., Murdoch C.E., Ali M., Purbrick S., Ravid R., Baxter G.S., et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 141 (2004) 580-585
29. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483 (2000) 285-293
30. Kobayashi T., and Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 68-69 (2002) 557-573
31. Ivey K.N., and Srivastava D. The paradoxical patent ductus arteriosus. J Clin Invest 116 (2006) 2863-2865
32. Lewis R.A., Soter N.A., Diamond P.T., Austen K.F., Oates J.A., and Roberts II L.J. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129 (1982) 1627-1631
33. Abel M.H., and Baird D.T. The effect of 17 beta-estradiol and progesterone on prostaglandin production by human endometrium maintained in organ culture. Endocrinology 106 (1980) 1599-1606
34. Smith S.K., Abel M.H., Kelly R.W., and Baird D.T. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 88 (1981) 434-442
35. Breyer M.D., and Breyer R.M. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63 (2001) 579-605
36. Lai J., Jin H., Yang R., Winer J., Li W., Yen R., et al. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 271 (1996) H2197-H2208
37. Camras C.B., Siebold E.C., Lustgarten J.S., Serle J.B., Frisch S.C., Podos S.M., et al. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 96 (1989) 1329-1336 [discussion: 36-7]
38. Alexander C.L., Miller S.J., and Abel S.R. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother 36 (2002) 504-511
39. Jones R.L., Qian Y., Wong H.N., Chan H., and Yim A.P. Prostanoid action on the human pulmonary vascular system. Clin Exp Pharmacol Physiol 24 (1997) 969-972
40. Coleman R.A., Smith W.L., and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46 (1994) 205-229
41. Schubert R., Serebryakov V.N., Engel H., and Hopp H.H. Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase. Am J Physiol 271 (1996) C1203-C1211
42. Clapp L.H., Turcato S., Hall S., and Baloch M. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur J Pharmacol 356 (1998) 215-224
43. Olschewski H., Rose F., Schermuly R., Ghofrani H.A., Enke B., Olschewski A., et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102 (2004) 139-153
44. Walch L., Labat C., Gascard J.P., de Montpreville V., Brink C., and Norel X. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 126 (1999) 859-866
45. Dumble L.J., Gibbons S., Tejpal N., Chou T.C., Redgrave N.G., Boyle M.J., et al. 15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine. Transplantation 55 (1993) 1124-1128
46. Aronoff D.M., Peres C.M., Serezani C.H., Ballinger M.N., Carstens J.K., Coleman N., et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 178 (2007) 1628-1634
47. Coquette A., Boeynaems J.M., and Vray B. Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis. Eur J Pharmacol 226 (1992) 1-4
48. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 170-172
49. Kallen A.J., Lederman E., Balaji A., Trevino I., Petersen E.E., Shoulson R., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29 (2008) 342-349
50. Oudiz R.J., Widlitz A., Beckmann X.J., Camanga D., Alfie J., Brundage B.H., et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 126 (2004) 90-94
51. Fischer M., Bhatnagar J., Guarner J., Reagan S., Hacker J.K., Van Meter S.H., et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 353 (2005) 2352-2360
52. Nalesnik J.G., Jones L., and Kraus S.R. Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes. J Urol 172 (2004) 151-152
53. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 (1999) 1193-1226
54. Lai Y.J., Pullamsetti S.S., Dony E., Weissmann N., Butrous G., Banat G.A., et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 178 (2008) 188-196
55. Clapp L.H., Finney P., Turcato S., Tran S., Rubin L.J., and Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 26 (2002) 194-201
56. Vane J., and Corin R.E. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 26 (2003) 571-578
57. Melian E.B., and Goa K.L. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 62 (2002) 107-133
58. GeneraMedix, Inc. announces sale of innovative epoprostenol formulation to Actelion Ltd. improved formulation for treatment of patients with PAH. GeneraMedix, Available from: http://www.generamedix.com/news_090223.asp; [accessed 10.03.09].
59. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
60. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
61. Kuhn K.P., Byrne D.W., Arbogast P.G., Doyle T.P., Loyd J.E., and Robbins I.M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
62. Shapiro S.M., Oudiz R.J., Cao T., Romano M.A., Beckmann X.J., Georgiou D., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 (1997) 343-349
63. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
64. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
65. Galie N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
66. Magnani B., and Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 17 (1996) 18-24
67. Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., and Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124 (1996) 820-824
68. Olschewski H., Rohde B., Behr J., Ewert R., Gessler T., Ghofrani H.A., et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124 (2003) 1294-1304
69. Schermuly R.T., Schulz A., Ghofrani H.A., Breitenbach C.S., Weissmann N., Hildebrand M., et al. Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J Aerosol Med 19 (2006) 353-363
70. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
71. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
72. Hoeper M.M., Leuchte H., Halank M., Wilkens H., Meyer F.J., Seyfarth H.J., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
73. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
74. Laliberte K., Arneson C., Jeffs R., Hunt T., and Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
75. Wade M., Baker F.J., Roscigno R., DellaMaestra W., Hunt T.L., and Lai A.A. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 44 (2004) 83-88
76. McSwain C.S., Benza R., Shapiro S., Hill N., Schilz R., Elliott C.G., et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 48 (2008) 19-25
77. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
78. McLaughlin V.V., Gaine S.P., Barst R.J., Oudiz R.J., Bourge R.C., Frost A., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
79. Gomberg-Maitland M., Tapson V.F., Benza R.L., McLaughlin V.V., Krichman A., Widlitz A.C., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
80. Ivy D.D., Claussen L., and Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 99 (2007) 696-698
81. Rubenfire M., McLaughlin V.V., Allen R.P., Elliott G., Park M.H., Wade M., et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 132 (2007) 757-763
82. Sitbon O., Manes A., Jais X., Pallazini M., Humbert M., Presotto L., et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 49 (2007) 1-5
83. Barst R.J., Galie N., Naeije R., Simonneau G., Jeffs R., Arneson C., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28 (2006) 1195-1203
84. In: McLaughlin V., Rubin L., Benza R., Channick R., Vosswinkel R., and Tapson V. (Eds). Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH) [abstract A965] (2008 May 16-21), American Thoracic Society Meeting, Toronto, Canada
85. Freedom-C trial of oral treprostinil in pulmonary arterial hypertension fails to meet primary endpoint. United Therapeutics, Available from: http://ir.unither.com/releasedetail.cfm?ReleaseID=347887; [accessed 6.03.09].
86. Demolis J.L., Robert A., Mouren M., Funck-Brentano C., and Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol 22 (1993) 711-716
87. Galie N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
88. Barst R.J., McGoon M., McLaughlin V., Tapson V., Rich S., Rubin L., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
89. Nakamura A., Yamada T., and Asaki T. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. Bioorg Med Chem 15 (2007) 7720-7725
90. Asaki T., Hamamoto T., Sugiyama Y., Kuwano K., and Kuwabara K. Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists. Bioorg Med Chem 15 (2007) 6692-6704
91. Kuwano K., Hashino A., Noda K., Kosugi K., and Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, NS-304, ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, MRE-269, on rat pulmonary artery. J Pharmacol Exp Ther (2008)
92. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 336 (1997) 111-117
93. Haworth S.G. The management of pulmonary hypertension in children. Arch Dis Child 93 (2008) 620-625
94. Denyer J., Nikander K., and Smith N.J. Adaptive Aerosol Delivery (AAD) technology. Expert Opin Drug Deliv 1 (2004) 165-176
95. Highland K.B., Strange C., Mazur J., and Simpson K.N. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 124 (2003) 2087-2092
96. Oudiz R.J., and Farber H.W. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 157 (2009) 625-635
97. Narine L., Hague L.K., Walker J.H., Vicente C., Schilz R., Desjardins O., et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 21 (2005) 2007-2016
98. Miller S.B. Prostaglandins in health and disease: an overview. Semin Arthritis Rheum 36 (2006) 37-49